MediciNova, Inc.

NASDAQ:MNOV

Biotechnology

Healthcare
$1.33 -1.32%

-$0.02 today

Market cap
$68.14M
Beta
0.62
P/E (TTM)
-5.6
EPS (TTM)
-$0.24
52W Low $1.17High $1.96

Volume 0.12M

Average 0.04M

MNOV Interest Expense

Cost of servicing the company's debt during the period.

MediciNova, Inc.NASDAQ: MNOV

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How MNOV compares with its peers on the latest reported figures

  • MNOV's LTM Mar 2026 interest expense of $0 is the 5th highest of the 11 companies compared; the peer median is $0.
  • Interest expense amounts to 0.0% of revenue for MNOV, versus a peer median of 22.4%.
MNOV Competitors Peer median
Interest Expense for MNOV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CBUSCibus, Inc.LTM Mar 2026$17.98M -47.5%+641.6%419.6%
FBIOFortress Biotech, Inc.LTM Mar 2026$9.57M -28.8%-13.9%14.5%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.78M -17.6%+33.0%30.4%
VXRTVaxart, Inc.LTM Mar 2026$2.33M -26.3%+29.3%0.9%
MNOVMediciNova, Inc.LTM Mar 2026$0 ——0.0%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
IMUXImmunic, Inc.LTM Mar 2026$0 ———
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 ———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
XBITXBiotech Inc.LTM Mar 2026$0 -100.0%——
BMEABiomea Fusion, Inc.LTM Mar 2026$0 ———
Peer median (excluding MNOV) $0-28.8%+31.2%22.4%

Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.04M01M0409.66K
Cost of Revenue0000378.61K
Gross Profit4.04M01M031.05K
Gross Margin100.0%—100.0%—7.6%
Research & Development8.1M9.14M5.66M7.2M7.15M
Selling, General & Admin5.72M5.48M5.24M5.48M6.16M
Operating Expenses14.25M14.63M10.9M12.68M13.31M
Depreciation & Amortization26.15K17.71K20.3K21.08K20.1K
EBITDA(10.11M)(14.05M)(8.55M)(11.02M)(11.97M)
EBITDA Margin-250.3%—-854.8%—-2922.4%
Operating Income(10.22M)(14.63M)(9.9M)(12.68M)(13.28M)
Operating Margin-253.0%—-990.0%—-3242.5%
Interest Income143.63K809.67K1.83M1.67M1.3M
Interest Expense00000
Other Income / Expenses84.13K562.39K1.33M1.63M1.29M
Income Before Tax(10.13M)(14.07M)(8.57M)(11.04M)(11.99M)
Pre-Tax Margin-250.9%—-856.8%—-2927.3%
Income Tax Expense2.57K2.82K3.05K5.54K5.99K
Net Income(10.13M)(14.07M)(8.57M)(11.05M)(12M)
Net Margin-251.0%—-857.2%—-2928.8%
EPS (Basic)(0.21)(0.29)(0.17)(0.23)(0.24)
EPS (Diluted)(0.21)(0.29)(0.17)(0.23)(0.24)
Weighted Avg Shares48.6M49.05M49.05M49.05M49.06M
Weighted Avg Shares (Diluted)48.6M49.05M49.05M49.05M49.06M

MediciNova, Inc.

NASDAQ:MNOV

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.